TCT 2020 | Efficacy of Cerebral Protection Device TriGUARD 3 During TAVR

Cerebral protection device TriGUARD 3, designed to cover all supra-aortic vessels during transcatheter aortic valve replacement (TAVR), is safe to use, according to the outcomes of the REFLECT II study.

TCT 2020 | Eficacia del dispositivo de protección cerebral TriGUARD 3 durante el TAVI

The technical feasibility of the device, which requires transfemoral access, does not seem to have an impact over clinical events.

The primary safety endpoint was a VARC-2-defined composite of all-cause mortality, all stroke, life-threatening bleeding, acute kidney injury, coronary artery obstruction requiring intervention, and valve dysfunction requiring a repeat procedure. The 30-day rate was 15.9%, showing non-inferiority compared to previous studies.

The device failed to provide a clinical benefit in terms of stroke and burden of cerebral lesions. Diffusion-weighted magnetic resonance imaging analysis suggests that bigger lesions–most likely to cause symptoms–could be reduced.


Read also: TCT 2020 | Initial Studies Show Incredible Results with Lithotripsy in Calcified Lesions.


TriGUARD 3 bears the CE mark but has not yet been approved by the United States Food and Drug Administration (FDA) for use in said country. This device consists in a micromesh that covers all three supra-aortic vessels to deflect any debris created during TAVR or other structural intervention. It is inserted through a transfemoral access and its release system is similar to that of TAVR; consequently, its use is intuitive.

The REFLECT II study was conducted in 25 sites in the United States, where patients were randomized 2:1 to TAVR plus protection device or TAVR without protection. The valve was implanted in all patients, and TriGUARD 3 was deployed and retrieved in all cases.

At 30 days, the safety endpoint was more common in the TriGUARD group, although the difference did not reach statistical significance (15.9% vs. 7.0%; p = 0.11). Authors explained that the higher amount of events in the TriGUARD arm was due to bleeding at the TAVR access site and not to the device in itself.


Read also: TCT 2020 | Crushed Prasugrel Administration prior PCI.


There was also a numeric trend towards more stroke events in the TriGUARD arm (8.3% vs. 5.3%; p = 0.57). Once more, authors explained that there were no differences as regards immediate stroke; events were accumulated throughout 30 days and may not be related to the TriGUARD device.

Original Title: A randomized evaluation of the TriGUARD3 cerebral embolic protection device to reduce the impact of cerebral embolic lesions after transcatheter aortic valve implantation: the REFLECT II trial.

Reference: Moses JW. Presentado en el congreso TCT 2020 virtual.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...